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Microglia, which constitute the resident macrophages of the central nervous system (CNS), are generally
considered as the primary immune cells in the brain and spinal cord. Microglial cells respond to various
factors which are produced following nerve injury of multiple aetiologies and contribute to the develop-
ment of neuronal disease. Chemokine (C–C motif) ligand 1 (CCL-1), a well-characterized chemokine
secreted by activated T cells, has been shown to play an important role in neuropathic pain induced
by nerve injury and is also produced in various cell types in the CNS, especially in dorsal root ganglia
(DRG). However, the role of CCL-1 in the CNS and the effects on microglia remains unclear. Here we
showed the multiple effects of CCL-1 on microglia. We ﬁrst showed that CCR-8, a speciﬁc receptor for
CCL-1, was expressed on primary cultured microglia, as well as on astrocytes and neurons, and was
upregulated in the presence of CCL-1. CCL-1 at concentration of 1 ng/ml induced chemotaxis, increased
motility at a higher concentration (100 ng/ml), and increased proliferation and phagocytosis of cultured
microglia. CCL-1 also activated microglia morphologically, promoted mRNA levels for brain-derived neu-
rotrophic factor (BDNF) and IL-6, and increased the release of nitrite from microglia. These indicate that
CCL-1 has a role as a mediator in neuron-glia interaction, which may contribute to the development of
neurological diseases, especially in neuropathic pain.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction We have previously discovered that CCL-1 was producedCCL-1, also known as thymus-derived chemotactic agent 3
(TCA-3), is secreted by activated macrophages, T-cell, mast cells
and endothelial cells, and has important role as the chemoattrac-
tant for neutrophils and monocytes [1]. Although effects of CCL-1
on the peripheral immune cell are well characterized, the role of
CCL-1 in the CNS remains unclear.mainly in the DRG and spinal cord after peripheral nerve injury
and contributed to the development of neuropathic pain [2]. We
also showed that the expression of the speciﬁc CCL-1 receptor
CCR-8 was up-regulated in the ipsilateral superﬁcial dorsal horn
after spinal nerve ligation, not only in neurons but also in microglia
and astrocytes. Microglial cells are generally considered as the pri-
mary immune cells in the CNS [3,4], and play important roles in the
development of neuropathic pain [5]. One of the main functions of
microglia in those pathological conditions is that they act as a
source and a target of chemokine actions, also in an auto/paracrine
fashion. Chemokines including CCL-2 (monocyte chemoattractant
protein 1), CCL-21, or CX3CL1 (fractalkine) have been shown to
serve as signals from endangered neurons to microglia [6]. Though
microglial expression at transcriptional and/or protein level has
been documented for many chemokine receptors [7], the func-
tional role of CCL-1/CCR-8 has not been reported yet.
In the present study, we demonstrated that CCL-1 stimulated
microglial migration, proliferation and phagocytosis, and release
of BDNF and IL-6 in vitro, which may contribute to the neuropathic
pain due to nerve injury.
2. Materials and methods
The study was approved by the Animal Research Committee of
Kyushu University.
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Mouse microglial cells were isolated from the mixed cultures of
cerebrocortical and spinal cord from postnatal days 1–3 ddY mice
(Kyudo, Tosu, Japan), as described previously [8,9]. In brief, tissue
was trypsinized for 3 min and dissociated with a ﬁre-polished
pipette. Mixed glial cells were cultured for 9–12 days in Dulbecco’s
Modiﬁed Eagle Medium (DMEM; Nissui, Tokyo, Japan) supple-
mented with 10% Hyclone fetal bovine serum (FBS; Hyclone Labra-
tories, UT, USA), 2 mM L-glutamine, 0.2% D-glucose, 5 lg/ml insulin,
0.37% NaHCO3, 100 U/ml penicillin, 100 lg/ml streptomycin at
37 C in a 10% CO2, with medium changes every 3 days. Microglial
cells were then separated from the underlying astrocytic layer by
gently shaking the ﬂask for 2 h at 37 C in a shaker-incubator
(120 rpm). After unattached cells were removed, microglial cells
were isolated as strongly adhering cells. The purity of microglia
was >98%, which was evaluated by staining with Iba1 (ionized
calcium-binding adapter molecule-1), a marker for microglia/mac-
rophage. Primary cultured neurons from the cerebral cortex were
obtained from embryonic day 14–16 (E14–16) ddY mice as
described previously [10]. Brieﬂy, neurons were cultured at 37 C
in a 10% CO2 incubator for 5–7 days with neurobasal medium
(GIBCO, NY, USA) containing 2% B27 supplement (GIBCO) and
0.5 mM L-glutamine (GIBCO).
2.2. Immunocytochemical analysis
Primary cultured cells were ﬁxed with 4% paraformaldehyde for
30 min at room temperature and permeabilized with 0.1% Triton
X-100 in phosphate buffered saline (PBS; 8.1 mM Na2HPO4,
1.5 mM KH2PO4, 2.7 mM KCl, 136.9 mM NaCl, pH 7.4) for 5 min,
followed by treating with blocking solution (Block Ace; Dainippon
Pharmaceutical, Japan) for 30 min at room temperature. Cells were
incubated with primary antibodies: Iba1 (1:2000, Wako, Japan),
CD11b (1:500, Serotec, UK), CCR-8 (1:500, Enzo, PA, USA), Ki67
(1:1000, Abcam, UK), NeuN (1:200, Millipore, CA, USA), MAP2
(1:1000, SIGMA, MO, USA), GFAP (glial ﬁbrillary acid protein,
1:800, Millipore), phalloidin (mouse anti-Texas Red-conjugated
phalloidin, 2 U/ml, Invitrogen, CA, USA) overnight at 4 C. The cells
were washed with PBS, and then incubated for 3 h at room temper-
ature with secondary antibody (IgG-conjugated Alexa Fluor™ 488
or 568 or 593, 1:1000, Molecular Probes, OR, USA). The cells were
washed with PBS and treated with DAPI (300 nM, Molecular
Probes) for 10 min, then washed with PBS. Slides were cover-
slipped with permaﬂuor aqueous mounting medium. The sections
were analyzed using a confocal laser scanning microscope
(LSM510META, Carl Zeiss, Germany).
2.3. Real time reverse transcription (RT) polymerase chain reaction
(PCR)
Cultured microglia cells were plated in 60 mm dishes (106 cells/
dish) and incubated for 24 h and collected after treatment of CCL-1
(R&D systems, MN, USA). They were subjected to total RNA extrac-
tion according to the protocol of the manufacture and puriﬁed with
QIAamp RNA Blood Mini (Qiagen, Valencia, CA, USA). The amount
of total RNA concentration was measured using Smart Spec™
3000 (Bio Rad, Tokyo, Japan). Total RNA (175 ng) was converted
to cDNA by reverse transcription, using random 9 mer (Takara,
Otsu, Japan) and RNA PCR kit (Takara). The forward and reverse
primers and the estimated product size were as follows: CCL-1
mRNA (50-TTCCCCTGAAGTTTATCCAGTGTT-30; 50-TGAACCCACGTT
TTGTTAGTTGAG-30), 124 bp; CCR-8 mRNA (50-ACGTCACGATGACC-
GACTACTAC-30; 50-GAGACCACCTTACACATCGCAG-30), 301 bp; b-
actin mRNA (50-TTGCTGACAGGATGCAGAAGGAG-30; 50-GTGGA
CAGTGAGGCCAGGAT-30), 127 bp; IL-10 mRNA (50-GTCATCGATTTCTCCCCTGTG-30; 50-CCTTGTAGACACCTTGGTCTTGG-30), 93 bp;
CCL-2 mRNA (50-CGGAACCAAATGAGATCAGAA-30; TGTGGAAAA
GGTAGTGGATGC-30), 26 bp; TNF-a mRNA (50-CCACCACGCTCTTC
TGTCTAC-30, 50-TGGGCTACAGGCTTGTCACT-30) 848 bp; IL-1b
mRNA (50-CTCCATGAGCTTTGTACAAGG-30; 50-TGCTGATGTACCAG
TTGGGG-30) 245 bp; IL-6 mRNA (50-ACACTCCTTAGTCCTCGGCCA-
30; 50-CACGATTTCCCAGAGAACATGTG-30) 129 bp; BDNF mRNA
(50-TGCAGGGGCATAGACAAAAGG-30; 50-CTTATGAATCGCCAGC-
CAATTCTC-30), 110 bp. All primers were purchased from Sigma
Aldrich Japan (Tokyo, Japan). PCR ampliﬁcation was undertaken
for Thunderbird Sybr qPCR Mix (Toyobo, Osaka, Japan) in Applied
Biosystems 7500 Real-Time PCR System (Applied Biosystems
Japan, Tokyo, Japan). Each reaction volume consisted of 12.5 ll
Thunderbird Sybr qPCR Mix, 0.05 ll 50ROX reference dye, 1 ll
mix of forward and reverse primers (0.3 lM each), and 11.45 ll
RNAase free water containing cDNA (17.5 ng). PCR was done by
15 s denaturation at 95 C, and annealing/extending at 60 C for
40 cycles. Each mRNA expression level was normalized by b-actin.
The mRNA expression was calculated relative to b-actin using the
DDCT algorithm.2.4. Microchemotaxis assay
Microglial chemotactic migration was tested with 48-well
microchemotaxis Boyden chamber (Neuroprobe, MD, USA) [11].
Upper and lower wells were separated by polycarbonate ﬁlter
(8 lm pore size; Poretics, CA, USA). Primary cultured microglial
cells (200  104 cells/ml) in 50 ll of serum-free DMEMwere added
to the upper wells, and the lower wells contained the same med-
ium with or without (control) CCL-1 and other drugs if mentioned.
The chamber was incubated at 37 C and 10% CO2 for 90 min. Cells
remaining on the upper surface of the membrane were removed by
wiping, and migrated cells were subjected to Diff-Quik stain kit
(Sysmex Corp., Kobe, Japan). Rate of microglial migration was cal-
culated by counting cells in four random ﬁelds of each well.2.5. Motility experiment
Experiments were performed as described [9]. Cultured microg-
lial cells were seeded on glass-bottom dishes (Matsunami, Osaka,
Japan) at a density of 4  104 cells/dish in serum-free DMEM.
Motility of microglia under controlled temperature (37 C) and
gas (10% CO2/90% humidity) was monitored with a time-lapse
videomicroscopy system (Nikon Instec, Fukuoka, Japan). The video
camera (Nikon inverted microscope, TE-2000-E) was controlled by
Luminavision software (MITANI, Osaka, Japan). Images were
acquired at 1 min intervals for 1 h in the presence or absence (con-
trol) of drugs, and stored on a computer and analyzed by Dipp-Mo-
tion 2D (DITECT, Tokyo, Japan). Serum-free DMEM was used as
control.2.6. Phagocytosis assay
Microglial cells seeded on the slide glass (4  104 cells/dish)
were pre-incubated with 4 lg/ml ﬂuorescent zymosan beads
(Zymosan A (S. cerevisiae) BioParticles, Alexa Fluor 488 conjugate,
Invitrogen, UK) in serum-free DMEM for 1 h, then incubated with
CCL-1 with or without other drugs for another 1 h. Beads-treated
microglial cells were ﬁxed with 4% paraformaldehyde, treated with
anti-Iba1 (1:2000, overnight), then incubated with Alexa Fluor
568-conjugated goat anti-rabbit IgG (1:1000). Series of Z-stack
images (every 0.6 lm) were examined with an All-in-One ﬂuores-
cence microscope (BIOREVO BZ-9000; Keyence, Osaka, Japan) for
3D-analysis of each phagocytic cell.
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For cultured microglia, the number of CD11b- and Ki67-positive
cells (CD11b+ and Ki67+, respectively) was counted in ten areas of
450 lm  450 lm, and the total number of CD11b+ cells in the
same area was obtained for each group. The ratio of Ki67+/
CD11b+ microglial cells was normalized to CD11b+cells. Using the
same method, the number of Iba1- and CCR-8-positive cells were
counted in ten areas of 150 lm  150 lm.2.8. Measurement of nitrite production
The nitrite accumulated in the culture medium was measured
as an indicator of NO production using the Griess reagent kit (Pro-
mega, Madison, WI, USA). Cell culture media were centrifuged at
4 C for 5 min and the supernatant was subjected to measurement
of nitrite.2.9. Statistical analysis
All data are presented as mean ± SEM. The statistical analyses of
the results were evaluated by using two-tailed Student’s unpaired
t-test, one-way ANOVA followed by Dunnett’s test or two-way
ANOVA followed by Tukey–Kramer test. P < 0.05 was considered
statistically signiﬁcant.Fig. 1. Expression of CCR-8 in microglia, astrocytes and neurons. (A) Immunostaining fo
Immunostaining for GFAP (red) and CCR-8 (green) in primary cultured astrocytes. Sca
cultured neurons. Scale bar = 20 lm. (D) Immunostaining for MAP2 (red) and CCR-8 (gr
expression in primary microglia derived from the cortex and the spinal cord by RT-PCR a
Iba1+ cells in cultured microglia with or without (control) application of CCL-1 (50 ng/ml)
t-test). (G) Relative expression of CCL-1 mRNA in astrocytes, microglia and neurons (%
ANOVA followed by Tukey–Kramer tests). (For interpretation of the references to colour3. Results
3.1. Expression of CCR-8 in microglia, astrocytes and neurons
Weﬁrst examined the expression of CCR-8, a speciﬁc receptor for
CCL-1, in primary cultured microglia, astrocytes and neurons. Cul-
tured cells were co-stainedwith CCR-8 and several glial or neuronal
markers. We identiﬁed CCR-8 expression in microglia (Fig. 1A),
astrocytes (Fig. 1B) and neurons (Fig. 1C and D). We further con-
ﬁrmed expression of CCR-8 mRNA in cultured microglia derived
from cortex and the spinal cord, showing the similar expression le-
vel (Fig. 1E). The spleen was used as a positive control. The ratio of
CCR-8-positive microglia was 31.0 ± 1.69%, which was increased
signiﬁcantly by application of CCL-1 (50 ng/ml) for 1 h (to
43.23 ± 2.36%, n = 10, Fig. 1F). The relative expression level of CCL-
1 mRNA was 1129.84 ± 115.13% in neurons and 206.68 ± 10.56%
in microglia compared to that of astrocytes (Fig. 1G).
3.2. Effects of CCL-1 on microglial chemotaxis and motility
The addition of CCL-1 to the lower well of the Boyden chamber
increased microglial migration, with more cells on the lower mem-
brane surface compared to that of control (Fig. 2A). CCL-1 (1.0, 5.0,
10.0, 50.0, 100.0 ng/ml) induced a concentration-dependent in-
crease in microglial chemotaxis (424.8 ± 13.9%, 569.8 ± 23.6%,
878.8 ± 30.0%, 925.9 ± 50.0%, 892.8 ± 43.3%, respectively; n = 24)
(Fig. 2B). Next, we measured the total migration distance of ther Iba1 (red) and CCR-8 (green) in primary cultured miroglia. Scale bar = 20 lm. (B)
le bar = 50 lm. (C) Immunostaining for NeuN (red) and CCR-8 (green) in primary
een) in primary cultured neurons. Scale bar = 20 lm. (E) CCR-8 and b-actin mRNA
nalysis. Spleen is positive control. (F) The ratio of CCR-8+/Iba1+ cells normalized by
for 1 h. Data represent mean ± SE. (n = 10) ⁄⁄P < 0.01. (two-tailed Student’s unpaired
of astrocytes). Data represent mean ± SE (n = 4). ⁄⁄P < 0.01 vs. astrocytes (one-way
in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 2. Effects of CCL-1 on microglial chemotaxis, motility and proliferation. (A and B) CCL-1-induced microglial chemotaxis determined by Boyden chamber. (A) Microglial
staining on the lower surface of polycarbonate ﬁlter 90 min after application of CCL-1 (50 ng/ml) or control (serum-free DMEM). (B) Quantiﬁcation of microglial chemotaxis
induced by CCL-1 (0.1, 1.0, 5.0, 10.0, 50.0 and 100.0 ng/ml) or control (serum-free DMEM). Data represent mean ± SE. (n = 10) ⁄⁄P < 0.01 vs. control (one-way ANOVA followed
by Dunnett’s test). (C) Motility of CCL-1-stimulated microglial cells. Total distance of microglial cells stimulated by CCL-1 (100 ng/ml) or control (serum-free DMEM) for 1 h.
Data represent mean ± SE. (n = 40) ⁄P < 0.05 vs. control (one-way ANOVA followed by Dunnett’s test). (D) Immunostaining for phalloidin (red) and Iba1 (green) in cultured
microglia 0.5 h and 2 h after application of CCL-1 (50 ng/ml). Scale bar = 20 lm. (E) Immunostaining for CD11b (red) and Ki67 (green) in cultured microglia 0.5 h and 2 h after
application of CCL-1 (50 ng/ml) or control (serum-free DMEM). Scale bars = 20 lm. (F) The ratio of Ki67+/CD11b+ microglial number normalized by CD11b+ number in
cultured microglia with or without application of CCL-1 (50 ng/ml) for 0.5 and 2 h. Data represent mean ± SE (n = 10). ⁄⁄P < 0.01 (two-way ANOVA followed by Tukey–Kramer
test). (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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creased the total migration distance signiﬁcantly (from 42.5 ± 3.9
to 25.86 ± 1.71 lm; n = 40), showing that CCL-1 increased microg-
lial motility (Fig. 2C).3.3. Effects of CCL-1 on microglial proliferation
To investigate the effects of CCL-1 on microglial morphology,
cells exposed to CCL-1 (50 ng/ml) for 0.5 h or 2 h were stained with
Iba1 (green) and phalloidin (F-actin marker, red) to visualize actin
polymerization. Exposure to CCL-1 induced membrane rufﬂing in
microglia (Fig. 2D). We also stained with CD11b (red) and Ki67
(proliferation marker, green) with or without CCL-1 (50 ng/ml)
for 0.5 h and 2 h to investigate the change in proliferation
(Fig. 2E). The number of Ki67-positive cells signiﬁcantly increased
at 0.5 h (from 41.52 ± 2.2 to 74.6 ± 2.2%; n = 10) and at 2 h (from
37.04 ± 5.0 to 69.7 ± 6.1%; n = 10) after application of CCL-1
(Fig. 2F).3.4. Effects of CCL-1 on microglial phagocytosis
The effect of CCL-1 on microglial phagocytosis was assayed by
Z-stack 3D imaging (Fig. 3A and B). Application of different concen-
tration of CCL-1 (5–50 ng/ml) tended to increase the number of
microglia phagocytizing beads (Fig. 3C), and, at 50 ng/ml signiﬁ-
cantly increased the average number of beads phagocytosed per
cell (Fig. 3D).
3.5. Effects of CCL-1 on microglial neurotrophic and proinﬂammatory
factors
Various factors produced by activated microglia were analyzed
in terms of mRNA levels. BDNFmRNA signiﬁcantly increased in cul-
tured microglia at 1 and 4 h after application of 50 ng/ml CCL-1
(173.2 ± 4.3% and 175.7 ± 20.0%, respectively; n = 3) (Fig. 4A). IL-6
mRNA transiently increased only at 4 h (158.8 ± 16.6%; n = 3) after
CCL-1 application (Fig. 4B). On the other hand, mRNAs for TNF-a,
CCL-2, IL-1b and IL-10 did not change after CCL-1 application
Fig. 3. Effects of CCL-1 on microglial phagocytosis. (A and B) 3D-images of microglial phagocytosis of ﬂuorescent zymosan beads (green) after application of CCL-1 (50 ng/ml).
Immunostaining for Iba1 (red) in cultured microglia in control (serum-free DMEM) (A) and 1 h after application of CCL-1 (B). (C) The distribution chart of phagocytized beads
in cultured microglia 1 h after application of CCL-1. (D) The number of phagocytized beads per one cultured microglia increased signiﬁcantly with 50 ng/ml CCL-1. Data show
mean ± SE (n = 10). ⁄⁄P < 0.01 vs. control (one-way ANOVA followed by Dunnett’s test). (For interpretation of the references to colour in this ﬁgure legend, the reader is
referred to the web version of this article.)
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increased NO release from microglia at 4, 6 and 12 h (from
1.01 ± 0.05 to 1.48 ± 0.06 lM, 1.32 ± 0.09 lM, 2.14 ± 0.04 lM,
respectively; n = 3) (Fig. 4G).
4. Discussions
We have previously reported that expression of CCL-1 mRNA
was detected in the ipsilateral DRG and spinal cord, and expression
of CCR-8 protein was upregulated in the spinal cord after partial
sciatic nerve ligation. Thus, we showed that CCL-1 might be one
of the key mediators involved in the development of neuropathic
pain following peripheral nerve injury [2].
The present study demonstrates that CCL-1, as well as other
chemokines, serves as chemoattractant for microglia, and induces
proliferation and phagocytosis of microglia. We further showed
that CCL-1 induced expression of neurotrophic and proinﬂamma-
tory factors in cultured microglia.
We conﬁrmed that CCL-1 speciﬁc receptor, CCR-8, were ex-
pressed on primary cultured microglia (Fig. 1A), while CCL-1 mRNA
wasmost strongly expressed in neurons (Fig. 1G). This indicates that
CCL-1worksasamediatorbetweenneuronandmicroglia in theCNS.A key aspect of microglial response to damage is an increase in
the microglial population at the site of injury. This is achieved
mainly by proliferation and migration of the resident microglia.
It has been shown that following peripheral nerve injury microglia
accumulated in the dorsal horn of the spinal cord [5,12,13]. Migra-
tion of microglia is thought to be orchestrated by various chemo-
tactic agents that are released at the site of injury. CCL-2 and
CX3CL-1 have been implicated in microglial migration to the site
of injury after peripheral nerve injury [14,15]. Increase in intracel-
lular calciummobilization and actin rearrangement as well as mor-
phological change in microglia was also reported with CX3CL-1
[16]. Here we showed that CCL-1 induced microglial chemotactic
migration, motility and proliferation (Fig. 2).
Another key function of microglia within the CNS is the clear-
ance of neurotoxic molecules, cellular debris or microbes via
phagocytosis to maintain neural networks [17]. In the present
study, we showed that CCL-1 signiﬁcantly increased microglial
phagocytosis (Fig. 3). It is uncertain whether this microglial func-
tion plays a role in restoring transmission through the clearance
of degenerating synaptic terminal or synaptic stripping [18,19].
Although we do not have direct evidence for the removal of syn-
apses within the dorsal horn or for the clearance of cellular debris
Fig. 4. Effects of CCL-1 on the production of microglial neurotrophic and proinﬂammatory factors. Expression of mRNA of cytokine (TNF-a, IL-6, IL-1b, IL-10), chemokine
(CCL-2) and growth factors (BDNF) in cultured microglia (A–F) and the release of NO from cultured microglia (G) after application of CCL-1 (50 ng/ml). Each mRNA value was
normalized to the control level. Data represent mean ± SE (n = 3). ⁄⁄P < 0.01, ⁄P < 0.05: vs. control (one-way ANOVA followed by Dunnett’s test).
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by CCL-1 might play a role in restoring homeostasis after periphe-
ral nerve injury.
CCL-1 also changed microglial morphology mediated by actin
polymerization (Fig. 2D). Cell migration, morphological change
and phagocytic activity are all regulated by reorganization of actin
cytoskeleton. In particularly, characteristic morphological remod-
eling of migrating cell deﬁned as a ‘membrane rufﬂing’ is induced
by actin polymerization [20–22], suggesting that CCL-1 affects ac-
tin polymerization in microglia.
Once stimulated through ‘danger’ stimuli, microglia secrete
cytokines and BDNF, which directly affect synaptic transmission
through enhancing dorsal horn neuron excitability [23,24]. These
cytokines released by microglia can induce central sensitization
via distinct mechanism [25]. IL-6 regulates inhibitory neurotrans-
mission by reducing the frequency of spontaneous inhibitory
postsynaptic currents and the amplitude GABA- and glycine-in-
duced currents [24]. BDNF from activated microglia induces a
depolarising shift in equilibrium potential for Cl ions in spinal
neurones, shifting the reversal potential for GABA currents and
switching inhibitory transmission to excitatory transmission
[23]. At the same time, BDNF contributes to the development
and maintenance of neuropathic pain by activating the NR2B-con-
tainig NMDA receptors [26]. Furthermore, peripheral nerve injury-
induced neuropathic pain is associated with iNOS induction and
NO release in the spinal cord [27]. Our data showed that BDNF
and IL-6 mRNA were signiﬁcantly increased, and that NO wasreleased, in cultured microglia after application of CCL-1 (Fig. 4).
These data indicated that microglia activated by CCL-1 could be
involved in maintaining neuropathic pain through the release of
IL-6, BDNF and NO.
Our previous study showed that intrathecal injection of CCL-1
increased the expression of CCR-8 not only in microglia but also
in astrocytes in the spinal cord [2]. In the present study, we also
showed that CCR-8 is expressed in cultured astrocytes (Fig. 1B),
suggesting that CCR-8 in astrocytes in the spinal cord may also
contribute to the pathological events after nerve injury.
In conclusion, we showed the expression of CCR-8 in both neu-
ron and glial cells and demonstrated the function of CCL-1/CCR-8
in cultured microglia. These indicate that CCL-1 induced by nerve
injury may work as a mediator in neuron-glia interaction, which
may contribute to the development of neurological diseases, espe-
cially in neuropathic pain.
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